memo-inOncology – SPECIAL ISSUE

Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research. Each SPECIAL ISSUE – CONGRESS REPORT features informative summaries of key topics from lung cancer to come out of a major international oncology congress.

The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.

Congress reports


Get a notification for every published memo – inOncology SPECIAL ISSUE. Register below.


    WCLC 2020 Cover

    memo – inOncology SPECIAL ISSUE

    Congress Report virtual WCLC 2020

    The memo inOncology WCLC 2020 congress report summarizes highlights from the latest clinical trials in lung cancer, with a focus on the role of adjuvant chemotherapy as well as targeted options and sequencing issues with KRAS, HER2 and ALK mutations. Novel treatment approaches in the EGFR-mutated NSCLC and small-cell lung cancer, relapsed malignant mesothelioma or pretreated NSCLC are among other topics reviewed.

    Now available!

    ASH 2020 English Cover

    memo – inOncology SPECIAL ISSUE

    Congress Report virtual ASH 2020

    The memoinOncology ASH 2020 congress report summarizes highlights from the latest clinical trials in B-Cell malignancies, with a focus on BTK inhibition and PD-1 inhibition. Indications include chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström’s macroglobulinemia, marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL), as well as other B-cell malignancies.



    All videointerviews from WCLC 2020

    Alex Spira highlights the advantages, shortcomings and the future potential of antibody-drug conjugates, the balance between pro- and anti-inflammatory cytokines within the tumor microenvironment, and the preclinical evidence for targeting inflammatory cytokines in advanced or metastatic non-small cell lung cancer.

    Luis M. Montuenga talks about factors that are impeding the implementation of low-dose computed tomography lung cancer screening at the global level and describes biomarkers/molecular technologies that are promising with respect to early detection of lung cancer. Moreover, he summarizes advantages and drawbacks of pan-cancer ctDNA analysis in liquid biopsy.

    Ming Tsao relates to the innovations of the 5th edition of the WHO classification of lung tumors in terms of additional chapters, new tumor types and grading systems. Additionally, he discusses the use of organoids as potential platforms for drug testing and biomarker validation, as well as miRNAs for early lung cancer detection.

    Sandip Patel discusses immunotherapy regimens for the treatment of patients with extended-stage SCLC, immune-related adverse events and how to identify, predict and prevent checkpoint-inhibitor induced pneumonitis. Additionally, he talks about post-pandemic cancer care delivery and what oncologists should keep in mind when using anti-PD-1 therapy.

    All videointerviews from virtual ASH 2020

    Steven P. Treon explains about innovative approaches in the treatment of Waldenström’s macroglobulinemia, future aspects and the successful use of BTK inhibition within niche groups of patients with WM, and potential benefits of BTK inhibitors regarding COVID-19 complications.

    Jorge Castillo relates to recent developments with respect to follicular lymphoma, multiple myeloma and Waldenström’s macroglobulinemia, current insights into CAR-T cell therapy in the setting of multiple myeloma, and the future of anti-CD38 antibody treatment in patients with Waldenström’s macroglobulinemia.

    Alessandra Tedeschi summarizes the results from the MAGNOLIA and iNNOVATE trials, relates to recent advances in the management of marginal zone lymphoma and discusses the effect of the introduction of BTK inhibition on the prognosis of patients with Waldenström’s macroglobulinemia.

    Stephen Opat discusses the requirements for treatment-free long-term remission in the setting of CLL and talks about the future of BTK inhibitors and promising combinations in B-cell malignancies in general, as well as the strengths and limitations of immune checkpoint inhibitors.